The Use of Transcranial Electrical Stimulation for Hallucinations
The Use of Transcranial Electrical Stimulation for Hallucinations
Schizophrenia is a serious mental health disorder that affects approximately 1% of the
 population. Auditory hallucinations are present in as many as 50-75% of patients with this
 diagnosis. The hallucinations experienced by patients vary greatly and can severely impact an
 individual's ability to function on a daily basis. In approximately 25-30% of these patients,
 medication is an ineffective mechanism for managing these symptoms. These hallucinations are
 known as medication refractory auditory hallucination (MRAH). For those whose auditory
 hallucinations do not respond to medication, non-surgical brain stimulation (NBS) has
 recently shown promise as a therapeutic intervention. Two specific types of NBS, called
 transcranial direct current stimulation (tDCS) and transcranial random noise stimulation
 (tRNS), seem particularly well suited to treating MRAH. They have yet to be compared to each
 other in large samples of patients with MRAH. The goal of the study is to investigate whether
 tRNS and tDCS are effective in the treatment of MRAH and if one is better than the other when
 compared directly.
Purpose and Background

 Schizophrenia is a serious mental health disorder with a constellation of positive, negative,
 and cognitive symptoms. Negative symptoms can include characteristics such as affective
 flattening, avolition, and alogia. Positive symptoms can include delusions, hallucinations,
 and disorganized speech or behavior. Auditory hallucinations (AH) are a hallmark of
 schizophrenia. They are reported in as many as 50-75% of patients with this diagnosis. The
 hallucinations experienced by patients vary greatly and can severely impact an individual's
 ability to function on a daily basis. In approximately 25-30% of patients diagnosed with
 schizophrenia, medication is an ineffective mechanism for managing these symptoms. These
 hallucinations are known as medication refractory auditory hallucinations (MRAH). They are
 defined as "the persistence of daily hallucinations without remission despite antipsychotic
 medication at an adequate dosage for at least three months".

 For those whose AH do not respond to medication, non-surgical brain stimulation (NBS) has
 recently shown promise as a therapeutic intervention. Specifically, the use of conductive
 electrical approaches termed transcranial electrical stimulation (tES). One method of tES
 that has received renewed interest due to its high portability, safety, and modulatory
 effects is transcranial direct current stimulation (tDCS). tDCS involves applying a weak
 electrical current using saline soaked electrode sponges, causing either increases or
 decreases in cortical excitability, respectively. Research has shown in both healthy subjects
 and patients (e.g. Alzheimer's disease, Parkinson's disease, stroke, and depression) that
 tDCS has the potential to modulate synaptic and neurotransmitter-dependent plasticity
 underlying changes in behavior and learning. Brunelin et al utilized tDCS to successfully
 reduce MRAH in a population diagnosed with schizophrenia. They were able to reduce AH by
 approximately 30% in their sample after 5 days of twice-daily treatment and this effect was
 maintained for approximately three months following treatment. This finding has yet to be
 replicated in a similar study.

 Along with tDCS, other new methods of NBS are being investigated across various disease
 states. One such study looked at the impact of tES on tinnitus. They tested whether type of
 tES made a difference in efficacy. They compared tDCS to tRNS. tRNS is very similar to tDCS
 except that it superimposes a random "white noise" gaussian waveform (from 0.1 hz to 640 hz)
 on top of the DC current. They found that tRNS induced a larger suppressive effect on
 tinnitus loudness and tinnitus-related distress when compared to tDCS. While their findings
 were in tinnitus, there are now multiple scholarly works describing a relationship of
 tinnitus and AH, possibly as a continuum or dimension underlying a variety of normal and
 disease states. This relationship suggests strategies found to be efficacious for tinnitus
 may in fact also be efficacious for AH. Recently, there was a case series showing possible
 efficacy in AH using tRNS.

 The purpose of the study is to examine the efficacy of tES in the treatment of MRAH of
 schizophrenia. The hypothesis is that tRNS will provide a larger reduction of AH in those
 with schizophrenia as compared to tDCS and no treatment (i.e. sham). Confirmation of this
 hypothesis would provide an exciting new option for treatment and may provide an even higher
 level of efficacy than is seen in tDCS. Further, this study would also provide replication of
 the work by Brunelin et al. and further support of tES as a compelling tool for the
 management of severe MRAH.

 Specific Aims

 1. Determine efficacy of tES as a treatment for MRAH. Hypothesis 1a: tDCS is more effective
 than sham in the treatment of MRAH shown by a reduction in both total and subscores of
 the AHRS. Hypothesis 1b: tRNS is more effective than both sham and tDCS in the treatment
 of MRAH as shown by a reduction in both total and subscores of the AHRS.

 2. Demonstrate safety and tolerability of tES in the treatment of MRAH. Hypothesis 2a: tDCS
 is safe and well tolerated in the treatment of MRAH as demonstrated by the TSEQ.
 Hypothesis 2a: tRNS is safe and well tolerated in the treatment of MRAH as demonstrated
 by TSEQ.

 3. Exploratory: Detect tES sensitive subtypes of AH based on the MUPS.

 Study Design

 This study is double-blind, between group, and sham-controlled. Subjects will be randomized
 to one of three arms (tRNS, tDCS, or sham) and will remain in that arm for the duration of
 the study. All subjects will complete an enrollment visit, ten treatment visits (2 visits per
 day), and 1, 3, and 6 month follow-up visits. Given that durability of effect has been
 suggested in the literature to be less than 6 months, patients will not be followed beyond 6
 months. The outcome of this study will be measured by standard auditory hallucination rating
 scales including the Positive and Negative Symptoms Scale (PANSS), Auditory Hallucinations
 Rating Scale (AHRS), and psychotic symptom rating scales (PSYRATS). Both the AHRS and PSYRATS
 are included as outcome measures to ensure generalizability to existing studies on tES (which
 use the AHRS) along with the broader body of AH research (which use the PSYRATS). The primary
 efficacy parameter will be the PSYRATS as this has shown the most evidence for accurate
 representation of AH.

 Clinical Significance

 -  This study will replicate and expand on previous research regarding the use of tES as a
 treatment for medication refractory auditory hallucinations

 -  Based on the findings, this study could have potential application as a non-invasive
 clinical intervention for treating MRAH which affect 25% of medicated patients with
 schizophrenia.

 Subjects

 This study will recruit individuals who are receiving outpatient services at the Minneapolis
 VA Medical Center, the University of Minnesota Department of Psychiatry, or the University of
 Minnesota Medical Center--Fairview. Patients will be referred by clinical staff from multiple
 departments including Mental Health, Polytrauma, and Social Work. Referral will be based on a
 clinical diagnosis of Schizophrenia or Schizoaffective disorder with medication refractory
 auditory hallucinations as assessed by the patient's clinical provider. Subjects will also
 have the ability to self-identify to flyers and local newspaper ads. Brunelin et al found a
 large and significant effect size (d=1.58, p<0.001) which the investigators have used to
 guide our power analysis. The investigators power analysis was performed for three arms using
 an alpha of 0.025, a power of 0.8, and a desired effect size of 1.00. This analysis results
 in a need for approximately 20 subjects per arm.

 Pre-screening.

 In order to reduce subject burden, the investigators will obtain a waiver of HIPAA
 authorization and informed consent for recruitment and screening to allow potential subjects
 to be pre-screened by chart review and in person or by telephone prior to scheduling
 potential participants for initial visit. Potential participants will be provided with
 information about the study and asked a series of questions to determine if they meet basic
 inclusion/exclusion criteria, such as a history of MRAH. They will be told about the basic
 aims of the study, and those interested in participating will be scheduled for an initial
 visit at which time they will complete consent paperwork.

 Initiation Visit

 The initiation visit (visit 1) starts with completion of informed consent, HIPAA, and the
 Modified Dysken Tool to assess capacity to consent. The participant must score 7 / 10 on the
 Dysken Tool in order to participate in the study. Should the participant score less than 7,
 s/he will be offered remedial teaching and re-assessment. Should the subject agree via
 consent and demonstrate capacity to consent, s/he is enrolled into the study. A full baseline
 evaluation is then performed. This includes assessment via MINI, MUPS, PANSS, AHRS, PSYRATS
 and Edinburgh Handedness Inventory.

 Treatment Visits

 Visits 2 - 10 are exclusively treatment visits. At each visit the participant completes the
 tES Side Effect Questionnaire (TSEQ) both pre and post treatment. Visits occur twice daily
 for 5 days. Visits must be spaced at least 2 hours apart. Depending on the arm participants
 have been randomized into, s/he will receive treatment with either tDCS, tRNS, or sham.
 Treatment will be provided using the Starstim Neurostimulator (Neuroelectrics, Inc.) This
 device has been approved for use in research in the United States without an investigational
 device exemption due to meeting criteria for non-significant risk. The same energetic
 parameters are used for both tDCS and tRNS (2mA for 20 min) as well as the same electrodes
 (SPONSTIM-25 25cm2 electrodes). Both tDCS and tRNS are initiated in a ramp-like fashion over
 10s from 0mA to 2mA. Once at 2mA, tDCS is held constant for the entire session whereas the
 tRNS consists of an alternating current of 2mA with a 0mA offset applied at random
 frequencies over a range of 0.1 to 100 Hz. The sham procedure involves only 40 sec
 stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the
 participant not be able to tolerate a current of 2mA due to pain or irritation, the current
 will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the
 participant will be removed from the study. Electrode placement is based on the international
 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a
 location corresponding approximately to the left dorsolateral prefrontal cortex, and the
 cathode placed at the midpoint between T3 and P3, a location corresponding to left
 temporo-parietal junction. Placement and parameters in tDCS are consistent with Brunelin et
 al, 2012). Placement and parameters in tRNS are consistent with. Stimulation setup and
 administration takes approximately 30 minutes.

 Visit 11 is run the same as visits 2 - 10 but after completion of the final (10th)
 stimulation session, the subject will again complete the PANSS, AHRS, and PSYRATS. This visit
 typically takes 90 minutes.

 Follow-Up Visits

 Visits 12 - 14 are follow-up assessment only visits and occur at 1 month, 3 month, and 6
 months post treatment. Participants will not receive stimulation but instead will be assessed
 via PANSS, AHRS, and PSYRATS.

 Missed Visits

 In the event that a participant misses a session of treatment, the session will be
 re-scheduled and treatment continued as soon as possible. The deviation from treatment will
 be noted in the study record.

 Informed Consent Process

 Consenting will take place in a private office at the Minneapolis VA Health Care System,
 University of Minnesota 717 Delaware office, the Ambulatory Research Center of the University
 of Minnesota Department of Psychiatry, or the UMPhysicians MINCEP clinic, depending on
 patient preference. Only the study staff obtaining consent, the subject, and any family
 members invited by the subject will be present. The research coordinator or other trained
 research staff will explain the study to the participants. After explaining the study, the
 participants will be allowed as much time as needed to review the HIPAA and consenting
 documents and ask any questions that might arise before making the decision to participate.
 If necessary, participants can delay participation for up to a week. Subjects will be allowed
 to review the consent form in private for as long as they need. Subjects will be allowed to
 ask any and all questions prior to providing consent. Study personnel obtaining consent will
 emphasize first and foremost that the study is voluntary and will not influence that
 subject's clinical care through the VA Medical Center, University of Minnesota Medical
 Center--Fairview, or the University of Minnesota Department of Psychiatry. To ensure
 comprehension of the information provided in the informed consent forms, participants will be
 asked to complete the Modified Dysken Tool and answer 7 out of 10 questions correctly.

 Indications of Lack of Capacity to Consent

 1. Potential participant has severe formal thought disorder that does not allow him or her
 to ask understandable questions or to answer the questions on the Dysken Tool

 2. Potential participant is unable to maintain attention to the description of the consent
 form long enough to perceive the individual basic points in the consent form

 3. Potential participant, either due to catatonia or otherwise, the potential participant
 cannot ask questions or respond sufficiently to indicate agreement

 4. Potential participant expresses delusions related to the research protocol that
 significantly distort his or her basic understanding of the research.

 No participant will be under legal commitment at the time of their consent or during their
 participation in the study.

 Data Analysis

 Data will be analyzed for group by time effects of stimulation method as compared to sham.
 Tolerability will also be assessed by looking at total side effect score compared to
 stimulation type. The data will be further analyzed using a clustering technique to
 understand the impact of symptom cluster and severity on overall treatment response.

 Potential Risks and Benefits

 This study involves the use of a tES device. With tES, both tDCS and tRNS are considered to
 be safe brain stimulation techniques that rarely result in adverse events. There is currently
 no evidence of serious side-effects. Criteria for discontinuation that may rarely occur are
 sores at the tCS administration site, headaches that impair global functioning, and worsening
 psychosis. Mild side-effects that typically resolve upon discontinuation tCS include light
 itching under the electrode at the beginning of administration, headache, fatigue, and
 nausea. The participant may choose to discontinue stimulation at any time during the session
 if experiencing discomfort or side effects. No other risks are anticipated. Nonetheless, in
 order to minimize risks, study staff will be using standards of administration that have been
 shown to be safe in numerous other studies and across more than 2000 studies using tES; this
 includes length of administration, magnitude of the current, size of electrode sponges used,
 and method of applying stimulation. Any unanticipated problems or adverse events will be
 reported according to MVAHCS standard operating procedure.

 Study staff will use private (medical or educational) records during the recruitment process.
 Therefore, the use of protected health information may be associated with negative feelings
 about sharing medical/educational history. Participants may experience mild stress and/or
 discomfort with completing surveys/interview. Participants could also experience temporary
 feelings of stress or mental fatigue due to the behavioral assessment measures used in the
 study.

 In addition, breach of confidentiality is a potential risk due to the use of sensitive
 private information. The results of this study may be published or presented but the
 participant's identity and records will not be revealed unless required by Federal Law. A
 Federal Law allows the U.S. Food and Drug Administration, Office for Human Research
 Protections, Government Accountability Office and other Federal agencies, the Research and
 Development Committee, representatives of USAMRMC, Henry M. Jackson Foundation, and/or the
 Institutional Review Board (IRB)/Human Studies Subcommittee of the VA Medical Center or
 University of Minnesota to review records. Because of the need for these inspections,
 absolute confidentiality cannot be guaranteed. However, every effort would be made to
 minimize these risks by providing the participant with a unique numerical identifier at the
 beginning of the study in order to protect their actual identification and maintain complete
 confidentiality.

 It is possible that a participant may have a reduction of symptoms from the tES treatment but
 there are no anticipated direct or societal benefits to participation in this research
 project.

 Research Monitor

 A MVAHCS or University of Minnesota staff will act as an independent research monitor for
 this study. Her/His duties may include discussing the research protocol and recruitment with
 the investigator and staff, monitoring utilization of the tES device, follow-up with any
 participants in which an adverse event was reported, and reporting findings to the IRB.

 Discontinuation Criteria

 Sores at the tES administration site Headaches that impair global functioning Worsening
 psychosis

 Privacy, Confidentiality, and Information Security

 Self-report data will be collected on paper and scanned and stored in a password protected
 database behind the MVAMC or University of Minnesota firewalls. All personal identifiers will
 be stored on the consent form and in a master participant list within the database. All other
 documents will contain the unique participant ID. All paper documents related to this study
 will be stored in a locked file cabinet within locked research study offices. Access to
 research data and documents will be restricted to research personnel listed on the study
 protocol.

 All data will be maintained at the MVAHCS and University of Minnesota indefinitely per
 requisite data retention policies. No data will be destroyed. Information regarding research
 results will not be shared with study participants.
Inclusion Criteria

 -  DSM-IV diagnosis of schizophrenia or schizoaffective disorder

 -  Age 18 to 64

 -  Experiencing medication refractory auditory hallucinations

 -  No antipsychotic medication changes or hospitalizations in the previous 4 weeks

 -  No substance dependence in the past six months and no substance abuse in the past
 month

 -  No clinically significant head injury or neurological disease

 -  Sufficient spoken English so as to be able to comprehend testing procedures

 -  No diagnosis of mental retardation or pervasive developmental disorder, i.e. premorbid
 IQ not less than 70

 -  Ability to give informed consent

 Exclusion Criteria

 -  History of seizures or epilepsy

 -  History of metallic cranial plates, screws, or implanted device

 -  History of craniotomy

 -  History of eczema on the scalp

 -  Diagnosis of bipolar disorder

 -  Diagnosis of major depression with psychotic features

 -  Unable to give informed consent